Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1998 2
1999 1
2001 2
2003 1
2008 1
2009 3
2010 7
2011 4
2012 9
2013 11
2014 8
2015 4
2016 15
2017 8
2018 7
2019 6
2020 2
2021 4
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

84 results
Results by year
Filters applied: . Clear all
Page 1
Transport-metabolism interplay.
Salphati L. Salphati L. Mol Pharm. 2009 Nov-Dec;6(6):1629-30. doi: 10.1021/mp900266r. Mol Pharm. 2009. PMID: 19961234 No abstract available.
Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.
Bronner SM, Merrick KA, Murray J, Salphati L, Moffat JG, Pang J, Sneeringer CJ, Dompe N, Cyr P, Purkey H, Boenig GL, Li J, Kolesnikov A, Larouche-Gauthier R, Lai KW, Shen X, Aubert-Nicol S, Chen YC, Cheong J, Crawford JJ, Hafner M, Haghshenas P, Jakalian A, Leclerc JP, Lim NK, O'Brien T, Plise EG, Shalan H, Sturino C, Wai J, Xiao Y, Yin J, Zhao L, Gould S, Olivero A, Heffron TP. Bronner SM, et al. Among authors: salphati l. Bioorg Med Chem Lett. 2019 Aug 15;29(16):2294-2301. doi: 10.1016/j.bmcl.2019.06.021. Epub 2019 Jun 26. Bioorg Med Chem Lett. 2019. PMID: 31307887
Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF Approach.
Kumar V, Yin M, Ishida K, Salphati L, Hop CECA, Rowbottom C, Xiao G, Lai Y, Mathias A, Chu X, Humphreys WG, Liao M, Nerada Z, Szilvásy N, Heyward S, Unadkat JD. Kumar V, et al. Among authors: salphati l. Drug Metab Dispos. 2021 Feb;49(2):159-168. doi: 10.1124/dmd.120.000204. Epub 2020 Oct 13. Drug Metab Dispos. 2021. PMID: 33051248
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy.
Song KW, Edgar KA, Hanan EJ, Hafner M, Oeh J, Merchant M, Sampath D, Nannini MA, Hong R, Phu L, Forrest WF, Stawiski E, Schmidt S, Endres N, Guan J, Wallin JJ, Cheong J, Plise EG, Lewis Phillips GD, Salphati L, Heffron TP, Olivero AG, Malek S, Staben ST, Kirkpatrick DS, Dey A, Friedman LS. Song KW, et al. Among authors: salphati l. Cancer Discov. 2022 Jan;12(1):204-219. doi: 10.1158/2159-8290.CD-21-0072. Epub 2021 Sep 20. Cancer Discov. 2022. PMID: 34544753 Free article.
Structure-Based Design of Potent, Selective, and Orally Bioavailable VPS34 Kinase Inhibitors.
Hu DX, Patel S, Chen H, Wang S, Staben ST, Dimitrova YN, Wallweber HA, Lee JY, Chan GKY, Sneeringer CJ, Prangley MS, Moffat JG, Wu KC, Schutt LK, Salphati L, Pang J, McNamara E, Huang H, Chen Y, Wang Y, Zhao W, Lim J, Murthy A, Siu M. Hu DX, et al. Among authors: salphati l. J Med Chem. 2021 Nov 15. doi: 10.1021/acs.jmedchem.1c01180. Online ahead of print. J Med Chem. 2021. PMID: 34779204
Design of Selective Benzoxazepin PI3Kδ Inhibitors Through Control of Dihedral Angles.
Safina BS, Elliott RL, Forrest AK, Heald RA, Murray JM, Nonomiya J, Pang J, Salphati L, Seward EM, Staben ST, Ultsch M, Wei B, Yang W, Sutherlin DP. Safina BS, et al. Among authors: salphati l. ACS Med Chem Lett. 2017 Aug 25;8(9):936-940. doi: 10.1021/acsmedchemlett.7b00170. eCollection 2017 Sep 14. ACS Med Chem Lett. 2017. PMID: 28947940 Free PMC article.
Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor.
Ma S, Suchomel J, Yanez E, Yost E, Liang X, Zhu R, Le H, Siebers N, Joas L, Morley R, Royer-Joo S, Pirzkall A, Salphati L, Ware JA, Morrissey KM. Ma S, et al. Among authors: salphati l. Br J Clin Pharmacol. 2019 Aug;85(8):1751-1760. doi: 10.1111/bcp.13961. Epub 2019 Jun 14. Br J Clin Pharmacol. 2019. PMID: 30973970 Free PMC article. Clinical Trial.
84 results